NRL-4 is being developed as a noninvasive, as-needed therapy for use outside the medical setting to address symptoms of acute agitation associated with schizophrenia and bipolar mania 1 in adults.*
The unique formulation of NRL-4 incorporates Intravail® from the Neurelis technology platform to address some of the challenges commonly encountered with intranasal administration.
NRL-4 is in the initial stage of development and presents a worldwide commercial opportunity for Neurelis.
*NRL-4 is a product candidate that has not been approved by the U.S. Food and Drug Administration for any indication.